HEALTH COVID-19 UPDATE
FDA Issues Guidance on Emergency Use Authorization for COVID-19 Vaccines Drug Makers Say Medication Will Not Be Ready by Election Day
By Sarafina Wright WI Contributing Writer The Food and Drug Administration (FDA) has issued guidance on emergency use authorization (EUA) for COVID-19 vaccines to further prevent the spread of the disease caused by the coronavirus. The agency said these recommendations apply, as of Oct. 9, to COVID-19 vaccines, which are
complex biological products that are intended to be administered to millions of individuals, including healthy people in an effort to thwart the pandemic. “Being open and clear about the circumstances under which the issuance of an emergency use authorization for a COVID-19 vaccine would be appropriate is critical to building public confidence and ensuring the use of COVID-19 vaccines once available,”
said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “The FDA’s new guidance on emergency use authorization of COVID-19 vaccines underscores that commitment by further outlining the process and recommended scientific data and information that would support an emergency use authorization decision.” Under the requirements for the long-awaited EUA, drug makers are to provide data that shows they followed clinical trial participants at least two months after their final vaccine injection. The FDA also wants companies to submit vaccines for authorization only after at least five severe cases of COVID-19 have been seen in volunteers who got the placebo, according to the guidance. “In addition to outlining our expectations for vaccine sponsors, we also hope the agency’s guidance on COVID-19 vaccines helps the public understand our science-based decision-making process that assures vaccine quality, safety and efficacy for any vaccine that is authorized or approved.” The agency says an EUA is a different standard than an approval, as
noted in the June guidance, however, in the case of an investigational vaccine developed for the prevention of COVID-19, both pathways require the submission of data demonstrating any vaccine’s safety and effectiveness. The FDA added that the guidance reiterates that any assessment regarding an EUA will be made on a caseby-case basis considering the target population, the characteristics of the product, the preclinical and human clinical study data on the product and the totality of the available scientific evidence relevant to the product. The guidance for EUA comes almost seven months after the out-
You’re Invited! Open House Event
break of the novel coronavirus that has resulted in more than 37 million global cases and one million plus deaths, according to John Hopkins’ COVID-19 tracker. In the U.S., there have been more than seven million cases and 200,000 deaths. The pandemic presents an extraordinary challenge to global health, according to the FDA. The agency added there are currently no FDA-licensed vaccines to prevent COVID-19, and the EUA policy is intended to remain in effect only for the duration of the public health emergency related to the disease. WI
ADMISSION PRIORITY PASS
Take a tour of our UnitedHealthcare Dual Complete® (PPO D-SNP) plan. Join us for a special open house event near you. If you have both Medicaid and Medicare, you may be eligible for a plan that offers you more benefits and features than you’re currently receiving at no additional cost. While you’re here, learn more about our plan benefits. You’ll enjoy: • Light snacks and refreshments • Informational hand-outs • UnitedHealthcare® giveaways • Health information
Bring a friend with you to enjoy the fun. All are welcome. Membership not required.
Your ticket to better health. Open House Event Date: 10/19/2020 Time: 11:00 a.m. to 1:00 p.m. Location: Courtyard Washingtonian DC/U.S. Capitol 1325 2nd St NE Washington, DC 20002
UHCCommunityPlan.com/DC Follow us! @UnitedHealthcareCommunityPlan
Hosted by:
Plans are insured through UnitedHealthcare Insurance Company or one of its affiliated companies, a Medicare Advantage organization with a Medicare contract and a contract with the State Medicaid Program. Enrollment in the plan depends on the plan’s contract renewal with Medicare. For accommodations of persons with special needs at meetings call 1-855-277-4716 TTY 711, 8 a.m. - 8 p.m. local time, 7 days a week. Eligible for a free drawing, gift, or prizes with no obligation to enroll. H2226_180731_033701_M CST30888A1_H2228-045-000
20 - OCTOBER 15 - 21, 2020
THE WASHINGTON INFORMER / WWW.WASHINGTONINFORMER.COM
